Immune Checkpoint Inhibitors Related Cystoureteritis:
A Case Report and Literature Review.
10.3779/j.issn.1009-3419.2023.106.17
- Author:
Shishi LI
1
;
Ke ZHENG
2
;
Yan XU
1
;
Mengzhao WANG
1
Author Information
1. Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
2. Department of Nephrology, Peking Union Medical College Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Acute kidney injury;
Cystoureteritis;
Immune checkpoint inhibitors;
Immune-related adverse events;
Lung neoplasms
- MeSH:
Humans;
Immune Checkpoint Inhibitors/therapeutic use*;
Lung Neoplasms/pathology*;
Adenocarcinoma of Lung/drug therapy*;
Tomography, X-Ray Computed
- From:
Chinese Journal of Lung Cancer
2023;26(9):709-716
- CountryChina
- Language:Chinese
-
Abstract:
A patient with advanced lung adenocarcinoma developed symptoms of frequent urination and urgent urination after 14 cycles of Pembrolizumab combined with chemotherapy. After making comprehensive analysis of the results of urine routine test, renal function, cystoscope and computed tomography (CT) examination, immune checkpoint inhibitors related cystoureteritis and acute kidney injury were considered. The patient's symptoms were relieved after discontinuation of Pembrolizumab combined with chemotherapy. However, the symptoms of urinary irritation worsened significantly after rechallenging Pembrolizumab combined with chemotherapy, and the symptoms was relieved after corticosteroids treatment. If patients develop urinary symptoms during immune checkpoint inhibitors treatment, immune checkpoint inhibitors related cystoureteritis should be considered for early differential diagnosis in order to implement appropriate treatment.
.
